OCTA-C1-INH / Octapharma - LARVOL DELTA

CONE-02: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Octapharma | Trial primary completion date: Jun 2027 ➔ Dec 2026

Trial primary completion date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

CONE-02: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Octapharma | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

CONE-02: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Octapharma | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

CONE-02: Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Octapharma | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

CONE-02: Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (clinicaltrials.gov) - P3 | N=124 | Not yet recruiting | Sponsor: Octapharma

New P3 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema